BETA
Your AI-Trained Oncology Knowledge Connection!
In this news roundup we highlight new FDA indications, the overuse of advanced imaging in breast cancer, MAPK inhibition in melanoma, and more.
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Belantamab Mafodotin Combo Has Meaningful Benefits in R/R Multiple Myeloma
Data from the DREAMM-7 trial may support belantamab mafodotin plus bortezomib and dexamethasone as a new standard of care in this patient population.
Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes
Patients with FRα+, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer may now be eligible for mirvetuximab soravtansine in the UK.
Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC
According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.
Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer
Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.
Novel Oral KRAS G12D Inhibitor Receives FDA Fast Track Designation in Advanced PDAC
Results from a phase 1/2a trial supported the designation for VS-7375 in those with PDAC harboring a KRAS G12D mutation.